Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 110

1.

Evaluation of impact of long-lasting insecticide-treated bed nets and point-of-use water filters on HIV-1 disease progression in Kenya.

Walson JL, Sangaré LR, Singa BO, Naulikha JM, Piper BK, Yuhas K, Onchiri FM, Otieno PA, Mermin J, Zeh C, Richardson BA, John-Stewart G.

AIDS. 2013 Jun 1;27(9):1493-501. doi: 10.1097/QAD.0b013e32835ecba9.

PMID:
23324658
2.

Are long-lasting insecticide-treated bednets and water filters cost-effective tools for delaying HIV disease progression in Kenya?

Verguet S, Kahn JG, Marseille E, Jiwani A, Kern E, Walson JL.

Glob Health Action. 2015 Jun 10;8:27695. doi: 10.3402/gha.v8.27695. eCollection 2015.

3.

Provision of bednets and water filters to delay HIV-1 progression: cost-effectiveness analysis of a Kenyan multisite study.

Kern E, Verguet S, Yuhas K, Odhiambo FH, Kahn JG, Walson J.

Trop Med Int Health. 2013 Aug;18(8):916-24. doi: 10.1111/tmi.12127. Epub 2013 May 10.

4.

Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.

Reynolds SJ, Makumbi F, Newell K, Kiwanuka N, Ssebbowa P, Mondo G, Boaz I, Wawer MJ, Gray RH, Serwadda D, Quinn TC.

Lancet Infect Dis. 2012 Jun;12(6):441-8. doi: 10.1016/S1473-3099(12)70037-3. Epub 2012 Mar 19.

5.

Total lymphocyte count as a possible surrogate of CD4 cell count to prioritize eligibility for antiretroviral therapy among HIV-infected individuals in resource-limited settings.

Bedell R, Heath KV, Hogg RS, Wood E, Press N, Yip B, O'Shaughnessy MV, Montaner JS.

Antivir Ther. 2003 Oct;8(5):379-84.

PMID:
14640384
6.

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study.

Ledergerber B, Egger M, Erard V, Weber R, Hirschel B, Furrer H, Battegay M, Vernazza P, Bernasconi E, Opravil M, Kaufmann D, Sudre P, Francioli P, Telenti A.

JAMA. 1999 Dec 15;282(23):2220-6.

PMID:
10605973
7.

HIV-infected ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea.

Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, Odongo G, Wetaka M, Mermin J, Tappero JW.

Clin Infect Dis. 2012 Apr;54(8):1204-11. doi: 10.1093/cid/cis013. Epub 2012 Mar 14.

8.

Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study.

Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, Ransom R, Weidle P, Lule J, Coutinho A, Solberg P.

Lancet. 2006 Apr 15;367(9518):1256-61.

PMID:
16631881
9.

Effect of micronutrient supplementation on disease progression in asymptomatic, antiretroviral-naive, HIV-infected adults in Botswana: a randomized clinical trial.

Baum MK, Campa A, Lai S, Sales Martinez S, Tsalaile L, Burns P, Farahani M, Li Y, van Widenfelt E, Page JB, Bussmann H, Fawzi WW, Moyo S, Makhema J, Thior I, Essex M, Marlink R.

JAMA. 2013 Nov 27;310(20):2154-63. doi: 10.1001/jama.2013.280923.

10.

No change in viral set point or CD4 cell decline among antiretroviral treatment-naïve, HIV-1-infected individuals enrolled in the Danish HIV Cohort Study in 1995-2010.

Helleberg M, Kronborg G, Larsen CS, Pedersen G, Pedersen C, Obel N, Gerstoft J.

HIV Med. 2013 Jul;14(6):362-9. doi: 10.1111/hiv.12016. Epub 2013 Feb 21.

11.

Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy.

Hogg RS, Yip B, Chan KJ, Wood E, Craib KJ, O'Shaughnessy MV, Montaner JS.

JAMA. 2001 Nov 28;286(20):2568-77.

PMID:
11722271
12.

Determinants of incident chronic kidney disease and progression in a cohort of HIV-infected persons with unrestricted access to health care.

Ganesan A, Krantz EM, Huppler Hullsiek K, Riddle MS, Weintrob AC, Lalani T, Okulicz JF, Landrum M, Agan B, Whitman TJ, Ross MJ, Crum-Cianflone NF; Infectious Disease Clinical Research Program HIV/STI Working Group.

HIV Med. 2013 Feb;14(2):65-76. doi: 10.1111/j.1468-1293.2012.01036.x. Epub 2012 Jul 19.

13.

Measures of site resourcing predict virologic suppression, immunologic response and HIV disease progression following highly active antiretroviral therapy (HAART) in the TREAT Asia HIV Observational Database (TAHOD).

Oyomopito R, Lee MP, Phanuphak P, Lim PL, Ditangco R, Zhou J, Sirisanthana T, Chen YM, Pujari S, Kumarasamy N, Sungkanuparph S, Lee CK, Kamarulzaman A, Oka S, Zhang FJ, Mean CV, Merati T, Tau G, Smith J, Li PC; TREAT Asia HIV Observational Database.

HIV Med. 2010 Sep;11(8):519-29. doi: 10.1111/j.1468-1293.2010.00822.x. Epub 2010 Mar 21.

14.

Barriers to antiretroviral initiation in HIV-1-discordant couples.

Guthrie BL, Choi RY, Liu AY, Mackelprang RD, Rositch AF, Bosire R, Manyara L, Gatuguta A, Kiarie JN, Farquhar C.

J Acquir Immune Defic Syndr. 2011 Nov 1;58(3):e87-93. doi: 10.1097/QAI.0b013e31822f064e.

15.

Coinfection with hepatitis viruses and outcome of initial antiretroviral regimens in previously naive HIV-infected subjects.

De Luca A, Bugarini R, Lepri AC, Puoti M, Girardi E, Antinori A, Poggio A, Pagano G, Tositti G, Cadeo G, Macor A, Toti M, D'Arminio Monforte A; Italian Cohort Naive Antiretrovirals Study Group.

Arch Intern Med. 2002 Oct 14;162(18):2125-32.

PMID:
12374521
16.

Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study.

Miller V, Mocroft A, Reiss P, Katlama C, Papadopoulos AI, Katzenstein T, van Lunzen J, Antunes F, Phillips AN, Lundgren JD.

Ann Intern Med. 1999 Apr 6;130(7):570-7.

PMID:
10189326
17.

Cost of community integrated prevention campaign for malaria, HIV, and diarrhea in rural Kenya.

Kahn JG, Harris B, Mermin JH, Clasen T, Lugada E, Grabowksy M, Vestergaard Frandsen M, Garg N.

BMC Health Serv Res. 2011 Dec 21;11:346. doi: 10.1186/1472-6963-11-346.

18.

Short-term and long-term clinical and immunological consequences of stopping antiretroviral therapy in HIV-infected patients with preserved immune function.

Imaz A, Olmo M, Peñaranda M, Gutiérrez F, Romeu J, Larrousse M, Domingo P, Oteo JA, Curto J, Vilallonga C, Masiá M, López-Aldeguer J, Iribarren JA, Podzamczer D; STOPAR study team.

Antivir Ther. 2013;18(1):125-30. doi: 10.3851/IMP2249. Epub 2012 Jul 18.

PMID:
22805174
19.

Prevalence and correlates of insecticide-treated bednet use among HIV-1-infected adults in Kenya.

Nnedu ON, John-Stewart GC, Singa BO, Piper B, Otieno PA, Guidry A, Richardson BA, Walson J.

AIDS Care. 2012;24(12):1559-64. doi: 10.1080/09540121.2012.674094. Epub 2012 Apr 26.

PMID:
22533793
20.

Socio-economic determinants of disease progression among HIV infected adults in Kenya.

Gitahi-Kamau NT, Kiarie JN, Mutai KK, Gatumia BW, Gatongi PM, Lakati A.

BMC Public Health. 2015 Jul 31;15:733. doi: 10.1186/s12889-015-2084-8.

Items per page

Supplemental Content

Write to the Help Desk